問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberC0524T09

2006-03-01 - 2012-03-31

Phase III

Study ended3

ICD-10M08.1

Juvenile ankylosing spondylitis

ICD-10M45.0

Ankylosing spondylitis of multiple sites in spine

ICD-10M45.1

Ankylosing spondylitis of occipito-atlanto-axial region

ICD-10M45.2

Ankylosing spondylitis of cervical region

ICD-10M45.3

Ankylosing spondylitis of cervicothoracic region

ICD-10M45.4

Ankylosing spondylitis of thoracic region

ICD-10M45.5

Ankylosing spondylitis of thoracolumbar region

ICD-10M45.6

Ankylosing spondylitis lumbar region

ICD-10M45.7

Ankylosing spondylitis of lumbosacral region

ICD-10M45.8

Ankylosing spondylitis sacral and sacrococcygeal region

ICD-10M45.9

Ankylosing spondylitis of unspecified sites in spine

ICD-10M48.8X1

Other specified spondylopathies, occipito-atlanto-axial region

ICD-10M48.8X2

Other specified spondylopathies, cervical region

ICD-10M48.8X3

Other specified spondylopathies, cervicothoracic region

ICD-10M48.8X4

Other specified spondylopathies, thoracic region

ICD-10M48.8X5

Other specified spondylopathies, thoracolumbar region

ICD-10M48.8X6

Other specified spondylopathies, lumbar region

ICD-10M48.8X7

Other specified spondylopathies, lumbosacral region

ICD-10M48.8X8

Other specified spondylopathies, sacral and sacrococcygeal region

ICD-10M48.8X9

Other specified spondylopathies, site unspecified

ICD-9720.0

Ankylosing spondylitis

  • Sponsor

  • Trial scale

  • Update

    2025/08/20

Investigators and Locations

Principal Investigator Chung-Ming Huang 風濕免疫科

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Study ended

Principal Investigator Joung-Liang Lan 風濕免疫科

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Study ended

Principal Investigator Wen Chan Tsai 風濕免疫科

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Study ended

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    35 participants

  • Global

    345 participants